Login to Your Account

TopoTarget Acquires Prolifix For Cash, Stock; Raises $15.3M

By Cormac Sheridan

Wednesday, June 12, 2002
Danish oncology firm TopoTarget A/S acquired UK cell cycle specialist Prolifix Ltd. in a combined cash and shares deal. The Copenhagen-based company also raised DKK120 million (US$15.3 million) in new funding, from HealthCap of Stockholm and BankInvest of Copenhagen. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription